RxDoctor Payments Data

Saagar Pandit, MD

Retina Specialist · Chicago, ILNPI 1598253437

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 53.5% of the total. 2025 is the largest year on record at $3,772, more than ten times the $60 reported in 2021.

$5,777in general payments, 2019–2025

Across 55 payments — averaging $105.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$3K
  • Regeneron Healthcare Solutions, Inc.$424
  • Genentech, Inc.$317
  • Genentech USA, Inc.$302
  • Eyepoint US, Inc.$301
  • Harrow Eye, LLC$246
  • plus $1K from 11 others
$1,447in research payments, 2019–2025

Across 8 payments — averaging $180.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$1K

What the payments were for

  • Consulting fees$2,59745%
  • Travel & lodging$1202%
  • Food & beverage$3,02052%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,777 in reported general payments places this provider in the 60th percentile of 70 retina specialist providers in Illinois.

See all retina specialist providers in Illinois

Medicare billing

Part B allowed, 2024
$131,152
Medicare patients
417
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate89$4,278
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim75$547
Brimonidine Tartrate15$53

Paid to pharmacies, not to this prescriber.

Other retina specialist in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →